Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and Zoledronic Acid. (TOPaZ). Please note, recruitment is temporarily suspended for TOPaZ. However, enrolled participants are still continuing within the trial.
If you have a diagnosis of Osteogenesis Imperfecta (OI) and are aged 18 years or over, you may be eligible for the Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic Acid (TOPaZ) Trial across the UK and Ireland. The study aims to determine whether a two-year spell with a treatment called Teriparatide (TPTD) followed by treatment with another drug called Zoledronic Acid (ZA) reduces the risk of broken bones occurring in people with OI as compared to standard care.
If you would like to find out more information, please contact the research team:
TOPaZ is a non-commercial trial sponsored by a partnership of the University of Edinburgh and NHS Lothian called ACCORD and funded by the UK National Institute for Health Research (NIHR).